![NVS-CECR2-1 rlukast [Epub ahead of print] PubMed](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M23629_1635914499.gif?v=1635914500)
Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
[Epub ahead of print] PubMed PMID: 25619871
making the blood thinner and improving circulation
2-b]pyrano[2''
Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298
5(11)12)2-4(9)10/h8-11
NVS-CECR2-1 rlukast [Epub ahead of print] PubMedNVS CECR2 1, a non BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS CECR2 1 binds to CECR2 BRD with high affinity (IC50=47 nM; KD=80 nM). NVS CECR2 1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2 independent mechanism. Product information CAS Number: 1992047 61 6 Molecular Weight: 495. 68
US$ 60.00
US$ 110.00
US$ 39.99
US$ 89.00
US$ 3279.50
US$ 3363.50
US$ 149.00
US$ 39.99